We narrowed to 8,901 results for: aav

#213917-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiLAMP5e3_GCaMP6f (#213917). In addition to the viral particles, you will also receive purified pAAV_BiLAMP5e3_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the Lamp5 interneuron-targeting enhancer E3. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#221463-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiPVe4_eGFP (#221463). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_eGFP plasmid DNA. Expression of EGFP under the control of the chandelier cell-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#37825-AAV11

Ready-to-use AAV11 particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

July 16, 2025

Academic Institutions and Nonprofits only

#135641-AAV1

Ready-to-use AAV1 particles produced from pAAV-S5E6-dTom-nlsdTom (#135641). In addition to the viral particles, you will also receive purified pAAV-S5E6-dTom-nlsdTom plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato in VIP cortical interneurons under the control of the E6 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Feb. 6, 2025

Academic Institutions and Nonprofits only

#99118-AAV2

Ready-to-use AAV2 particles produced from pAAV-CAG-tTA (#99118). In addition to the viral particles, you will also receive purified pAAV-CAG-tTA plasmid DNA. CAG-driven expression of tetracycline-controlled transactivator (tTA). These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Chan et al Nat Neurosci. 2017 Aug;20(8):1172-1179.

June 26, 2024

Academic Institutions and Nonprofits only

#83894-AAV2

Ready-to-use AAV2 particles produced from pAAV-hDlx-Flex-dTomato-Fishell_7 (#83894). In addition to the viral particles, you will also receive purified pAAV-hDlx-Flex-dTomato-Fishell_7 plasmid DNA. hDlx-driven, Cre-dependent expression of dTomato. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Feb. 5, 2024

Academic Institutions and Nonprofits only

#138328-AAV9

Ready-to-use AAV9 particles produced from pAAV-synapsin-HaloCaMP1b-EGFP (#138328). In addition to the viral particles, you will also receive purified pAAV-synapsin-HaloCaMP1b-EGFP plasmid DNA. Synapsin-driven HaloCaMP1b, a far-red calcium sensor, fused to EGFP. These AAV preparations are suitable purity for injection into animals.

Eric Schreiter

Deo et al Nat Chem Biol. 2021 Jun;17(6):718-723. d

Sept. 15, 2021

Academic Institutions and Nonprofits only

#138327-AAV9

Ready-to-use AAV9 particles produced from pAAV-synapsin-HaloCaMP1a-EGFP (#138327). In addition to the viral particles, you will also receive purified pAAV-synapsin-HaloCaMP1a-EGFP plasmid DNA. Synapsin-driven HaloCaMP1a, a far-red calcium sensor, fused to EGFP. These AAV preparations are suitable purity for injection into animals.

Eric Schreiter

Deo et al Nat Chem Biol. 2021 Jun;17(6):718-723. d

Sept. 15, 2021

Academic Institutions and Nonprofits only